Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VVOS
stocks logo

VVOS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
5.35M
+44.63%
-0.420
+50%
4.65M
+54.18%
-0.450
-0%
5.20M
+36.13%
-0.405
-26.36%
Estimates Revision
The market is revising Upward the revenue expectations for Vivos Therapeutics, Inc. (VVOS) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by -47.82%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.22%
In Past 3 Month
Stock Price
Go Down
down Image
-47.82%
In Past 3 Month
Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 6.75 USD with a low forecast of 6.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 6.75 USD with a low forecast of 6.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.150
sliders
Low
6.50
Averages
6.75
High
7.00
Current: 2.150
sliders
Low
6.50
Averages
6.75
High
7.00
H.C. Wainwright
NULL -> Buy
initiated
$7
2025-11-17
Reason
H.C. Wainwright
Price Target
$7
2025-11-17
initiated
NULL -> Buy
Reason
H.C. Wainwright initiated coverage of Vivos Therapeutics with a Buy rating and $7 price target. Vivos is a commercial-stage medical device company focused on the commercialization of non-surgical treatment of maxillofacial abnormalities of the mouth and jaws that are closely associated with breathing and sleep disorders, the analyst tells investors in a research note. The firm expects the company's new business model and initiatives to drive solid sales growth in the coming years.
Alliance Global Partners
Scott Henry
Buy -> Neutral
downgrade
2025-05-20
Reason
Alliance Global Partners
Scott Henry
Price Target
2025-05-20
downgrade
Buy -> Neutral
Reason
Alliance Global Partners analyst Scott Henry downgraded Vivos Therapeutics to Neutral from Buy with a price target of $2.25, down from $5.50. The firm views the company's visibility as low pending signs of execution for its new business model, which it says is unlikely before the second half of 2025. Vivos has limited financial resources to manage this uncertainty, the analyst tells investors in a research note. Alliance points out the company's Q1 results trailed forecasts as the business model shifts from dentists to sleep specialists.
Ascendiant Capital
Lucas Ward
Strong Buy
Maintains
$6.6 → $6.2
2025-04-15
Reason
Ascendiant Capital
Lucas Ward
Price Target
$6.6 → $6.2
2025-04-15
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vivos Therapeutics Inc (VVOS.O) is -1.29, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess Vivos Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.70
Current PE
-1.29
Overvalued PE
0.09
Undervalued PE
-5.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.72
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.50
Undervalued EV/EBITDA
-1.94

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.10
Current PS
0.00
Overvalued PS
4.26
Undervalued PS
-0.07
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

VVOS News & Events

Events Timeline

(ET)
2025-11-19
16:27:11
Vivos Therapeutics announces Q3 earnings per share of 49 cents, below consensus estimate of 51 cents.
select
2025-09-30 (ET)
2025-09-30
08:44:11
Vivos Therapeutics Reveals New Data on Vivos DNA Device Usage
select
2025-09-17 (ET)
2025-09-17
08:35:31
Vivos Therapeutics Reveals Trial Outcomes for Pediatric OSA Therapy
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-20Newsfilter
Vivos Therapeutics Sees Major Revenue Increase in Q3 2025

  • Financial Performance: Vivos Therapeutics reported a 78% sequential revenue growth in Q3 2025, driven by the acquisition of the Sleep Center of Nevada, with total revenue reaching $6.8 million for the quarter and $13.6 million for the nine months ended September 30, 2025.

  • Strategic Shift: The company is transitioning from a dental distribution model to direct affiliations and acquisitions of medical sleep practices, which is expected to enhance revenue streams and meet growing patient demand in the Las Vegas area.

  • Operational Challenges: Operating expenses increased by 74% to $8.7 million in Q3 2025 due to investments in personnel and infrastructure related to the SCN acquisition, leading to a higher operating loss of $4.7 million for the quarter.

  • Future Plans: Vivos is exploring additional market expansions and partnerships, including a management agreement with MISleep Solutions in Michigan, while continuing to optimize operations at SCN to reduce cash burn and aim for profitability in 2026.

[object Object]
Preview
4.0
11-17Benzinga
Alto Neuroscience Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Monday

  • Analyst Coverage Initiations: BTIG analyst Thomas Shrader initiated coverage on Alto Neuroscience (ANRO) with a Buy rating and a price target of $27, while B of A Securities analyst Travis Steed gave Masimo Corporation (MASI) a Neutral rating with a target of $162.

  • Ovid Therapeutics and Vivos Therapeutics Ratings: Leerink Partners analyst Marc Goodman rated Ovid Therapeutics (OVID) as Outperform with a price target of $5, and HC Wainwright & Co. analyst Yi Chen rated Vivos Therapeutics (VVOS) as Buy with a target of $7.

  • TAT Technologies Coverage: Benchmark initiated coverage on TAT Technologies Ltd. (TATT) with a Buy rating and a price target of $53.

  • Current Stock Prices: As of Friday, Alto Neuroscience closed at $12.11, Masimo at $151.12, Ovid at $1.3050, Vivos at $2.34, and TAT Technologies at $40.04.

[object Object]
Preview
9.0
09-29NASDAQ.COM
Biotech Surge on Friday: Clinical Advancements Drive Afternoon Gains

  • Enanta Pharmaceuticals Surge: Enanta Pharmaceuticals Inc. saw a significant after-hours increase of 20% to $9.48 following the announcement of upcoming topline results from its Phase 2b study on zelicapavir for treating RSV in high-risk adults.

  • Acumen Pharmaceuticals Rebound: Acumen Pharmaceuticals Inc. experienced a 12.67% rise in after-hours trading, driven by renewed interest in its Alzheimer's candidate, Sabirnetug, despite no new announcements on that day.

  • Delcath Systems Recovery: Delcath Systems Inc. rebounded 6.00% after hours to $11.39, likely fueled by investor interest in its CHOPIN Phase 2 trial data presentation related to a hepatic delivery system for metastatic colorectal cancer.

  • Nyxoah's Optimism: Nyxoah SA's shares rose 3.77% after hours, supported by positive investor sentiment regarding its international expansion and a recent patent infringement lawsuit against Inspire Medical Systems.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vivos Therapeutics Inc (VVOS) stock price today?

The current price of VVOS is 2.15 USD — it has increased 3.86 % in the last trading day.

arrow icon

What is Vivos Therapeutics Inc (VVOS)'s business?

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods that promote sleep wellness and health for patients suffering from breathing and sleep issues such as obstructive sleep apnea (OSA) and snoring in adults. The Company's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The Company's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The Company has sleep testing centers and associated medical sleep practice.

arrow icon

What is the price predicton of VVOS Stock?

Wall Street analysts forecast VVOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VVOS is 6.75 USD with a low forecast of 6.50 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vivos Therapeutics Inc (VVOS)'s revenue for the last quarter?

Vivos Therapeutics Inc revenue for the last quarter amounts to 6.78M USD, increased 75.73 % YoY.

arrow icon

What is Vivos Therapeutics Inc (VVOS)'s earnings per share (EPS) for the last quarter?

Vivos Therapeutics Inc. EPS for the last quarter amounts to -0.49 USD, increased 22.50 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vivos Therapeutics Inc (VVOS)'s fundamentals?

The market is revising Upward the revenue expectations for Vivos Therapeutics, Inc. (VVOS) for FY2025, with the revenue forecasts being adjusted by 2.34% over the past three months. During the same period, the stock price has changed by -47.82%.
arrow icon

How many employees does Vivos Therapeutics Inc (VVOS). have?

Vivos Therapeutics Inc (VVOS) has 109 emplpoyees as of December 05 2025.

arrow icon

What is Vivos Therapeutics Inc (VVOS) market cap?

Today VVOS has the market capitalization of 19.32M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free